Topic: mergers and acquisitions
Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.
A close look at SEC documents describing Lilly's bid for Loxo indicates more interest in targeted oncology than the deal's genesis might indicate, analysts say.
Mylan shelled out $9.4 million for Ascendis Health’s South African manufacturing plant that is focused on producing antiretrovirals to combat HIV.
The stagnant pharma M&A scene will turn around in 2019, especially with recent declines in biotech valuations, experts predict.
As GlaxoSmithKline sees new opportunity for Zejula beyond BRCA-mutated cancers, it's paying a large premium to acquire Tesaro.
Tesaro has reportedly tried to sell itself before, but to no avail. But its newly lowered share price may be sparking some new buyout interest.
Cambrex finalizes $425 million acquisition of dosage-form CDMO Halo Pharma and its two manufacturing plants.
Polisano Pharmaceuticals is now under the control of rail freight group Grampet after the company upped its stake in the drugmaker from 20% to 74%.
Bayer’s new billboards in St. Louis depict the iconic Gateway Arch planted in greenery to celebrate the close of the Monsanto acquisition.
A trial in a Delaware Court this week will determine if Fresenius can cancel its $4.3 billion buyout of competitor Akorn.